7.7.2022 18:09:05 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 17-2022 – Inside information - 7 July 2022

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces a capital increase by a nominal amount of DKK 21,917 divided into 21,917 new shares with a nominal value of DKK 1 each, in connection with the exercise of warrants.

At a meeting today, the non-executive board of directors of ViroGates has resolved that the trading window for Persons Discharging Managerial Responsibility was extended from 14 June to 14 July, all in compliance with MAR article 19.

The board of directors had received notices of exercise of warrants as follows:

The total shares issued by this resolution are 21,917 shares.

The warrants had been issued pursuant to articles 2.11 and 2.12 (as regards Jesper Eugen-Olsen (partly)) and 2.13 (as regards Thomas Krarup, Mark da Silva, Jakob Knudsen, and Jesper Eugen-Olsen (partly)) of the Company’s Articles of association.

The exercise price had been paid to the company’s bank account.

Accordingly, the board of directors resolved to issue 21,917 shares of the nominal value of DKK 1.00 each.

The total proceeds to the Company as a result of the subscription of shares amounts to DKK 800,000.75

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights from the time of the warrant holder’s exercise notice. ViroGates only has one class of shares.

The new shares are expected to be admitted to trading and official listing on NASDAQ First North Growth Market Copenhagen A/S after registration with the Danish Business Authority during the week commencing 18 July 2022 under the ISIN code for ViroGates A/S’ shares (DK0061030574).

Pursuant to section 32 of the Danish Capital Markets Act, it is hereby announced that the total nominal value of ViroGates A/S’ share capital increases from DKK 3,170,083 to DKK 3,192,00 after the capital increase which is made up of 3,192,000 shares of a nominal value of DKK 1 each, corresponding to 3,192,000 votes.

Furthermore, the Board resolved to issue 31,700 warrants to Patrik Dahlen and 9,510 warrants to Válerie Soulier according to the Articles section 2.13.1. The subscription price for the warrants will be DKK 57.8 being the officially quoted closing price as of today at Nasdaq First North Growth Market for each share at a nominal value of DKK 1. The subscription price will be adjusted in accordance with Articles 2.13.4.

The following number of warrants remain under the programs:

2015 allocation: 105,955 outstanding warrants

2019 allocation: 85,729 outstanding warrants

2022 allocation (incl. the above allocation): 83.71 outstanding warrants

The announcement can be found at: www.virogates.com/announcements

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Forward-looking statements

Certain information set forth and given in this announcement contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of ViroGates A/S (ViroGates); (ii) the expected development of ViroGates’ business, projects and joint ventures; (iii) execution of ViroGates’ vision and growth strategy, including with respect to future M&A activity and global growth; (iv) sources and availability of third-party financing for ViroGates’ projects; (v) completion of ViroGates’ projects that are currently underway, in development or otherwise under consideration; (vi) renewal of ViroGates’ current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this announcement are based upon what management of ViroGates believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. ViroGates undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

• 20220707-ViroGates Company ann. 17.pdf